New Biktarvy spot puts Gilead in top TV-spending ranks, right behind AbbVie and Pfizer

TV watcher image
Big-ticket pharma TV ads for the month of April included spots from Latuda, Eliquis and Taltz. (3dman_eu)

April was an impressive show of pharma TV ad strength even for long-standing top spender Humira. The AbbVie immunology med and megablockbuster topped the list in a big way this month with more than $45 million in national TV buys, according to data from real-time TV ad tracker iSpot.tv.

That’s up from $31.5 million in March, an increase of 45%. Pfizer's Xeljanz remained in second place for the third month in a row with $25.8 million in spending, and Gilead Sciences joined in the top 3 with $18.2 million.

But back to Humira, which is suffering under biosimilar assault in Europe. Executives warned in January that sales losses outside the U.S. could amount to $2 billion this year. And as analysts rework their forecast to account for the earlier-than-expected decline, AbbVie's going all out with its promotions in the U.S., where the med won't face biosimilars till 2023. Humira's global sales topped $20 billion last year, with $13.6 billion of that revenue coming from the U.S.

Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This on-demand webinar discusses the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

Meanwhile, Gilead is working to counter big losses in hepatitis C with new HIV pills, and one of its recent launches has hit the airwaves in a big way. Brand-new to the list this month is Gilead’s Biktarvy on the strength of its first big TV push after its February 2018 approval. The three-drug combo pill has already hit blockbuster status, racking up $1.18 billion in its first not-quite-full year of sales.

Meanwhile, Sunovion’s Latuda, Pfizer and Bristol Myers-Squibb’s Eliquis and Eli Lilly’s Taltz all rejoined the list in April. Overall, pharma TV ad spending among the top 10 stayed about the same month over month with a total of $168 million spent, down just slightly from $169 million in March.

1. Humira
Movement: Stayed same
What is it? AbbVie anti-inflammatory drug
Total estimated spending: $45.7 million (up from $$31.5 million in March)
Number of spots: 12 (Six for arthritis, four for ulcerative colitis/Crohn's disease, two for psoriasis)
Biggest-ticket ad: “Not Always Where I Needed to Be (est. $10.3 million)


2. Xeljanz
Movement: Stayed same
What is it? Pfizer oral rheumatoid arthritis and ulcerative colitis med
Total estimated spending: $25.8 million (down from $26.2 million in March)
Number of spots: Six
Biggest-ticket ad: “A Different Direction” (est. $12.6 million)



3. Biktarvy
Movement: Not on list last month
What is it? Gilead Sciences HIV 3-in-1 combo med
Total estimated spending: $18.2 million
Number of spots: One
Biggest-ticket ad: “Keep Being You”



4. Emgality
Movement: Stayed same
What is it? Eli Lilly anti-CGRP migraine treatment
Total estimated spending: $15.1 million (down from $16.7 million in March)
Number of spots: One
Biggest-ticket ad: “Pirates”



5. Latuda
Movement: Not on list last month
What is it? Sunovion Pharmaceutical antipsychotic
Total estimated spending: $12.9 million
Number of spots: One
Biggest-ticket ad: “Lauren’s Story”



6. Eliquis
Movement: Not on list last month
What is it? Pfizer and Bristol-Myers Squibb next-generation anticoagulant
Total estimated spending: $11.3 million
Number of spots: Three
Biggest-ticket ad: “Around the Corner” (est. $5.2 million)



7. Trulicity
Movement: Moved down from No. 6
What is it? Eli Lilly GLP-1 diabetes drug
Total estimated spending: $10.7 million (down from $13.5 million in March)
Number of spots: Six
Biggest-ticket ad: “I Can Do More: Wedding Planner” (est. $9.7 million)



8. Taltz
Movement: Not on list last month
What is it? Eli Lilly next-generation psoriasis treatment
Total estimated spending: $10.6 million
Number of spots: Four
Biggest-ticket ad: “Moving” (est. $3.8 million)



9. Ozempic
Movement: Moved up from No. 10
What is it? Novo Nordisk GLP-1 diabetes med
Total estimated spending: $9.1 million (down from $10.3 million in March)
Number of spots: One
Biggest-ticket ad: “Arcade: Oh, Oh, Oh, Ozempic”



10. Otezla
Movement: Moved down from No. 9
What is it? Celgene's oral treatment for plaque psoriasis
Total estimated spending: $12.4 million (down from $9.5 million in March)
Number of spots: One
Biggest-ticket ad: “Summer Days”

(Ad not available on iSpot at the request of Celgene.)

Suggested Articles

Alnylam is ready to follow on its Onpattro launch with an FDA nod for Givlaari. But the drug's safety profile is giving analysts reason to pause.

FDA nominee Stephen Hahn faced questions from Senators on Wednesday on topics including drug pricing, biosimilars, opioids and more.

BMS’ Opdivo-Yervoy combo been game-changing in late-stage melanoma. But when it comes to expanding the pair’s reach, the company has hit a roadblock.